However, the benefit of etoposide on EFS was mainly confirmed in patients with ALK positive ALCL patients, and only a trend of benefit was found in patients with other PTCL entities (such as ALK negative ALCL, AITL, and PTCL-NOS)11. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.